New Optical Imaging Could Improve Surgical Outcomes Following Cancer Resection
the Cancer Therapy Advisor take:
New optical imaging technology that is currently under development could “light up” cancer cells, allowing surgeons to remove more cancerous tissue than previously possible during procedures.
Development of the technology was spearheaded by Phillip Low, BS, the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University and the cofounder of On Target Laboratories.
Through the use of an optical imaging molecule known as OTL38, Low and fellow Purdue researchers are hoping to prove the safety and efficacy of the compound in patients with cancer. OTL38 achieved first-in-humans status at the Center for Human Drug Research at Leiden University.
“On Target Laboratories has developed small-molecules ligands, such as OTL38, that specifically target receptors overexpressed on solid tumors,” Dr. Low said. “We have attached them to proprietary fluorescent imaging agents that allow the cancers to light up during surgery. Surgery is pivotal for the treatment of solid tumors, and our developing technology could, in the future, be the guiding light for surgeons by enabling intra-operative visualization of most such tumors.”
He believes that further collaboration with surgeons at Leiden University will allow for better testing of the novel technology in different types of cancers.
“The image guided surgery program is a prime example of how novel molecules like OTL38 ideally should be developed,” said Adam Cohen, PharmD, CEO of the Center for Human Drug Research. “
New optical imaging technology that is currently under development could “light up” cancer cells.
The technology was developed by Philip Low, the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University, director of the Purdue University Center for Drug Discovery and co-founder of On Target Laboratories.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer